Exploiting loss of heterozygosity for allele-selective colorectal cancer chemotherapy.

导出 OA

翻译打印收藏纠错

作者： Veronica,Rendo ^[1] ; Ivaylo,Stoimenov ^[2] ; André,Mateus ^[1] ; Elin,Sjöberg ^[3] ; Richard,Svensson ^[1] ; Anna-Lena,Gustavsson ^[3] ; Lars,Johansson ^[4] ; Adrian,Ng ^[5] ; Casey,OʼBrien ^[5] ; Marios,Giannakis ^[6] ; Per,Artursson ^[2] ; Peter,Nygren ^[2] ; Ian,Cheong ^[3] ; Tobias,Sjöblom ^[4]

作者单位： Science for Life Laboratory, Department of Immunology, Genetics and Pathology, Uppsala University, SE-75185, Uppsala, Sweden. ^[1] Dana-Farber Cancer Institute, 450 Brookline Ave, 02115, Boston, MA, USA. ^[2] Uppsala Drug Optimization and Pharmaceutical Profiling Facility (UDOPP), SciLifeLab Chemical Biology Consortium Sweden (CBCS), Department of Pharmacy, Uppsala University, 75123, Uppsala, Sweden. ^[3] SciLifeLab Drug Discovery and Development Platform, ADME of Therapeutics facility (UDOPP), Department of Pharmacy, Uppsala University, 75123, Uppsala, Sweden. ^[4] Chemical Biology Consortium Sweden, Science for Life Laboratory, Division of Translational Medicine and Chemical Biology, Department of Medicinal Biochemistry and Biophysics, Karolinska Institute, 17177, Solna, Sweden. ^[5] Temasek Life Sciences Laboratory, 1 Research Link, NUS, 117604, Singapore, Singapore. ^[6] Science for Life Laboratory, Department of Immunology, Genetics and Pathology, Uppsala University, SE-75185, Uppsala, Sweden. tobias.sjoblom@igp.uu.se. ^[7]